September 11, 2023

In September 2023, the Extensive Urine Drug Confirmation Panel updated its reporting approach for Noroxymorphone in the presence of protein interferences, now reporting qualitatively when quantitation is hindered. Additionally, Quest Diagnostics discontinued the NK Cells, LGLs (CD57) test in October 2023, with the recommended replacement being the Lyme Antibodies IgG & IgM assay. These changes aim to maintain accuracy and reliability in patient testing.